# Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors

> **NCT06221774** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 42 (estimated)

## Conditions studied

- Clear Cell Renal Carcinoma
- Urothelial Carcinoma
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** TT-00420 + Toripalimab

## Key facts

- **NCT ID:** NCT06221774
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-01
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-11-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06221774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06221774, "Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06221774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*